Comparative Pharmacology
Head-to-head clinical analysis: HARVONI versus RIMANTADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HARVONI versus RIMANTADINE HYDROCHLORIDE.
HARVONI vs RIMANTADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fixed-dose combination of ledipasvir, an HCV NS5A inhibitor, and sofosbuvir, an HCV NS5B nucleotide polymerase inhibitor. Ledipasvir inhibits HCV NS5A protein essential for viral replication and assembly; sofosbuvir is a prodrug that after intracellular metabolism acts as a chain terminator by inhibiting NS5B RNA-dependent RNA polymerase.
Rimantadine is a tricyclic amine antiviral that inhibits influenza A virus replication by blocking the M2 proton ion channel, preventing viral uncoating and release of viral RNA into host cells.
One tablet (90 mg ledipasvir/400 mg sofosbuvir) orally once daily with or without food for 12 weeks. For treatment-naïve patients with genotype 1 and cirrhosis, 24 weeks may be considered. For genotype 4, 12 weeks recommended.
100 mg orally twice daily for 7 days; initiate within 48 hours of symptom onset.
None Documented
None Documented
Ledipasvir: 47 hours; Sofosbuvir: 0.5 hours; GS-331007 (predominant circulating metabolite): 27 hours; clinical context: supports once-daily dosing with no accumulation beyond steady state by day 7
25.4 hours (range 13–65 h); prolonged in elderly (38 h) and severe renal impairment (CrCl <10 mL/min: up to 130 h).
Ledipasvir: 86% fecal, 1% renal; Sofosbuvir: 80% renal (as inactive metabolite GS-331007), 14% fecal; GS-331007: 78% renal
Renal: 75% unchanged; fecal: <10%; biliary: minimal. Total clearance 2.5 mL/min/kg.
Category C
Category A/B
Antiviral
Antiviral